ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma.

作者: Masanori Onda , Satoru Matsuda , Shozo Higaki , Takuo Iijima , Jun-ichi Fukushima

DOI: 10.1002/(SICI)1097-0142(19960101)77:1<71::AID-CNCR13>3.0.CO;2-5

关键词: PathologyGene expressionCancer researchOsteosarcomaSurvival analysisMedicineErbBConventional OsteosarcomaImmunohistochemistryCancerSurvival rate

摘要: BACKGROUND It has been reported that the c-erbB-2 protooncogene is frequently amplified and overexpressed in many types of cancers, except sarcomas hematological malignancies. METHODS Expression ErbB-2 tumors 26 patients with conventional osteosarcoma was evaluated by immunoblotting. DNA from tissues expressed were analyzed Southern blot hybridization to examine gross rearrangement gene. The also surveyed for presence genetic mutation transmembrane domain polymerase chain reaction–single-stranded conformation polymorphism analysis. In addition, possible correlation expression gender, age, histopathologic subtype, response chemotherapy analyzed. Survival analysis performed Kaplan-Meier test using approximate chi-square statistic log-rank test. RESULTS The protein detected 11 (42%) immunoblot Expression confirmed immunohistochemical studies specific anti-ErbB-2 monoclonal antibody. However, neither amplification gene nor evidence significant found these osteosarcomas. examined immunoblotting most strongly correlated early pulmonary metastases (P < 0.05). Among entire group this study, life table survival apparent significantly worse than little 0.01). CONCLUSIONS In 42% osteosarcomas, tumor cells ErbB-2. metastasis poor rate patient. These data suggest plays a role aggressive growth promotion metastatic potential would be useful prognostic marker patients. Cancer 1996;77:71-8.

参考文章(56)
Carlos Cordon-Cardo, Michael F. Press, Dennis J. Slamon, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. ,vol. 5, pp. 953- 962 ,(1990)
C. I. Bargmann, R. A. Weinberg, Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. The EMBO Journal. ,vol. 7, pp. 2043- 2052 ,(1988) , 10.1002/J.1460-2075.1988.TB03044.X
Mario Campanacci, Bone and Soft Tissue Tumors ,(1990)
Ralph R. Weichselbaum, Junya Toguchida, Takao Yamamuro, Siri H. Dayton, Kanji Ishizaki, Masao S. Sasaki, Bruce Ritchie, John B. Little, Roberta L. Beauchamp, Guillermo E. Herrera, David W. Yandell, Yoshihiko Kotoura, Toshikazu Yamaguchi, Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Research. ,vol. 52, pp. 6194- 6199 ,(1992)
W J Gullick, P Kelly, Sainsbury, C Wright, A L Harris, B Angus, J Cairns, S Nicholson, C H Horne, Expression of c-erbB-2 Oncoprotein: A Prognostic Indicator in Human Breast Cancer Cancer Research. ,vol. 49, pp. 2087- 2090 ,(1989)
Hector Battifora, Tadashi Yamamoto, Jun Yokota, Martin J. Cline, Dujin Zhou, Association of Multiple Copies of the c-erbB-2 Oncogene with Spread of Breast Cancer Cancer Research. ,vol. 47, pp. 6123- 6125 ,(1987)
O Segatto, C R King, J H Pierce, P P Di Fiore, S A Aaronson, Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Molecular and Cellular Biology. ,vol. 8, pp. 5570- 5574 ,(1988) , 10.1128/MCB.8.12.5570
S Fukushige, K Matsubara, M Yoshida, M Sasaki, T Suzuki, K Semba, K Toyoshima, T Yamamoto, Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line Molecular and Cellular Biology. ,vol. 6, pp. 955- 958 ,(1986) , 10.1128/MCB.6.3.955
R. M. Hudziak, J. Schlessinger, A. Ullrich, Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells Proceedings of the National Academy of Sciences of the United States of America. ,vol. 84, pp. 7159- 7163 ,(1987) , 10.1073/PNAS.84.20.7159